A systematic review of GWAS identified SNPs associated with outcomes of medications for opioid use disorder

Abstract Background Patients with opioid use disorder (OUD) display an interindividual variability in their response to medications for opioid use disorder (MOUD). A genetic basis may explain the variability in this response. However, no consensus has been reached regarding which genetic variants significantly contribute to MOUD outcomes. Objectives This systematic review aims to summarize genome-wide significant findings on MOUD outcomes and critically appraise the quality of the studies involved. Methods Databases searched from inception until August 21st, 2020 include: MEDLINE, Web of Science, EMBASE, CINAHL and Pre-CINAHL, GWAS Catalog and GWAS Central. The included studies had to be GWASs that assessed MOUD in an OUD population. All studies were screened in duplicate. The quality of the included studies was scored and assessed using the Q-Genie tool. Quantitative analysis, as planned in the protocol, was not feasible, so the studies were analyzed qualitatively. Results Our search identified 7292 studies. Five studies meeting the eligibility criteria were included. However, only three studies reported results that met our significance threshold of p ≤ 1.0 × 10–7. In total, 43 genetic variants were identified. Variants corresponding to CNIH3 were reported to be associated with daily heroin injection in Europeans, OPRM1, TRIB2, and ZNF146 with methadone dose in African Americans, EYS with methadone dose in Europeans, and SPON1 and intergenic regions in chromosomes 9 and 3 with plasma concentrations of S-methadone, R-methadone, and R-EDDP, respectively, in Han Chinese. Limitations The limitations of this study include not being able to synthesize the data in a quantitative way and a conservative eligibility and data collection model. Conclusion The results from this systematic review will aid in highlighting significant genetic variants that can be replicated in future OUD pharmacogenetics research to ascertain their role in patient-specific MOUD outcomes. Systematic review registration number CRD42020169121.

Download Full-text

GWAS-identified genetic variants associated with medication-assisted treatment outcomes in patients with opioid use disorder: a systematic review and meta-analysis protocol

Systematic Reviews ◽

10.1186/s13643-020-01461-z ◽

2020 ◽

Vol 9 (1) ◽

Author(s):

Caroul Chawar ◽

Alannah Hillmer ◽

Stephanie Sanger ◽

Alessia D’Elia ◽

Balpreet Panesar ◽

...

Keyword(s):

Systematic Review ◽

Treatment Outcomes ◽

Genetic Variants ◽

Meta Analysis ◽

Opioid Use Disorder ◽

Opioid Use ◽

Medication Assisted Treatment ◽

Analysis Protocol

Download Full-text

Efficacy of Acupuncture for Treating Opioid Use Disorder in Adults: A Systematic Review and Meta-Analysis

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2018/3724708 ◽

2018 ◽

Vol 2018 ◽

pp. 1-15

Author(s):

Zhihan Chen ◽

Yitong Wang ◽

Rui Wang ◽

Jin Xie ◽

Yulan Ren

Keyword(s):

Systematic Review ◽

Assessment Tool ◽

Meta Analysis ◽

Sham Acupuncture ◽

Opioid Use Disorder ◽

Cochrane Central Register ◽

Opioid Use ◽

Link Type ◽

Registration Number

Objectives. To assess the efficacy of acupuncture in treating opioid use disorder (OUD). Design. Systematic review and meta-analysis. Methods. PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase, PsycINFO, Cumulative Index to Nursing and Allied Health Literature (CINAHL), Web of Science, ProQuest Dissertation and Theses, Allied and Complementary Medicine Database (AMED), Clinicaltrials.gov, and who.int/trialsearch were searched from inception to 23 December 2017. The methodological quality of selected studies and the quality of evidence for outcomes were assessed, respectively, by the Cochrane risk of bias assessment tool and the GRADE approach. Statistical analyses were conducted by RevMan 5.3. Results. A total of nine studies involving 1063 participants fulfilled the inclusion criteria. The results showed that acupuncture could be more beneficial than no treatment/sham acupuncture in terms of changes in craving for opioid (MD -2.18, 95% CI -3.10 to -1.26), insomnia (MD 2.31, 95% CI 1.97 to 2.65), and depression (SMD -1.50, 95% CI -1.85 to -1.15). In addition, these findings showed that, compared to sham electroacupuncture (EA), EA had differences in alleviating symptoms of craving (SMD -0.50, 95% CI -0.94 to -0.05) and depression (SMD -1.07, 95% CI -1.88 to -0.25) and compared to sham transcutaneous acupoint electrical stimulation (TEAS), TEAS had differences in alleviating symptoms of insomnia (MD 2.31, 95% CI 1.97 to 2.65) and anxiety (MD -1.26, 95% CI -1.60 to -0.92) compared to no treatment/sham TEAS. Conclusions. Acupuncture could be effective in treating OUD. Moreover, EA could effectively alleviate symptoms of craving for opioid and depression, and TEAS could be beneficial in improving symptoms of insomnia and anxiety. Nevertheless, the conclusions were limited due to the low-quality and small number of included studies. PROSPERO registration number is CRD42018085063.

Download Full-text

Quality of life as an outcome of opioid use disorder treatment: A systematic review

Journal of Substance Abuse Treatment ◽

10.1016/j.jsat.2017.01.019 ◽

2017 ◽

Vol 76 ◽

pp. 88-93 ◽

Cited By ~ 21

Author(s):

Jeremy W. Bray ◽

Brandon Aden ◽

Ashley A. Eggman ◽

Leah Hellerstein ◽

Eve Wittenberg ◽

...

Keyword(s):

Quality Of Life ◽

Systematic Review ◽

Opioid Use Disorder ◽

Opioid Use ◽

Disorder Treatment

Download Full-text

A Systematic Review of Opioid Use Disorder and Related Biomarkers

Frontiers in Psychiatry ◽

10.3389/fpsyt.2021.708283 ◽

2021 ◽

Vol 12 ◽

Author(s):

Bianca M. Bryant ◽

Ellen Eaton ◽

Li Li

Keyword(s):

Systematic Review ◽

Immune System ◽

Chronic Inflammation ◽

Treatment Options ◽

Case Series ◽

Opioid Use Disorder ◽

Original Research ◽

Opioid Use ◽

Eligibility Criteria ◽

Potential Biomarkers

The objective of this systematic review is to examine the relationship between opioid use disorder (OUD) and its related biomarkers, as well as the effects of pharmacotherapy for OUD on biomarkers. The eligibility criteria are the inclusion of human population studies focusing on biomarkers, including the immune system, related to OUD or opioid-related disorders. English, peer reviewed, original research, case studies or case series, and clinical trials were included in this review. Papers were excluded if they met one or more of the following criteria: animal studies, review articles, studies focusing only on OUD or opioid-related disorders without mention of potential biomarkers, studies focusing only on biomarkers and/or the immune system without relating to OUD or opioid-related disorders, and studies that focused on other substance use disorders other than OUD specifically. A PubMed, PsycINFO, and Cochrane databases search on August 25, 2020, yielded 101 results; only 14 articles met inclusion criteria that were included in this review. However, heterogeneity of study definitions and measurements should be noted. Various potential biomarkers indicated systemic, peripheral, and chronic inflammation in patients with OUD or opioid-related disorders. Medications, including buprenorphine and methadone, significantly decreased chronic inflammation in this population. Our results suggest that patients with OUD or opioid-related disorders have potential biomarkers that can be targeted to provide optimal treatment options for this population. A better understanding of potential biomarkers may assist to identify at-risk populations, monitor disease progression and treatment response, and develop therapeutic strategies for OUD.Systematic Review Registration: This review has been registered in PROSPERO (CRD42020202014).

Download Full-text

Methodological quality of guidelines for the management of opioid use disorder: A systematic review

Journal of Clinical Pharmacy and Therapeutics ◽

10.1111/jcpt.13449 ◽

2021 ◽

Author(s):

Abuzar Watan Pal ◽

Zoriah Aziz ◽

Adeeba Kamarulzaman

Keyword(s):

Systematic Review ◽

Methodological Quality ◽

Opioid Use Disorder ◽

Opioid Use

Download Full-text

Patient Experiences with the Transition to Telephone Counseling during the COVID-19 Pandemic

Healthcare ◽

10.3390/healthcare9060663 ◽

2021 ◽

Vol 9 (6) ◽

pp. 663

Author(s):

Augustine W. Kang ◽

Mary Walton ◽

Ariel Hoadley ◽

Courtney DelaCuesta ◽

Linda Hurley ◽

...

Keyword(s):

Patient Outcomes ◽

Interrater Reliability ◽

Telephone Counseling ◽

Patient Experiences ◽

Opioid Use Disorder ◽

Opioid Use ◽

Therapeutic Experience ◽

Perceived Impact

Background: To identify and document the treatment experiences among patients with opioid use disorder (OUD) in the context of the rapid move from in-person to telephone counseling due to the COVID-19 pandemic. Methods: Participants (n = 237) completed a survey with open-ended questions that included the following domains: (1) satisfaction with telephone counseling, (2) perceived convenience, (3) changes to the therapeutic relationship, (4) perceived impact on substance use recovery, and (5) general feedback. Responses were coded using thematic analysis. Codes were subsequently organized into themes and subthemes (covering 98% of responses). Interrater reliability for coding of participants’ responses ranged from 0.89 to 0.95. Results: Overall, patients reported that telephone counseling improved the therapeutic experience. Specifically, 74% of respondents were coded as providing responses consistently indicating “positive valency”. “Positive valency” responses include: (1) feeling supported, (2) greater comfort and privacy, (3) increased access to counselors, and (4) resolved transportation barriers. Conversely, “negative valency” responses include: (1) impersonal experience and (2) reduced privacy. Conclusions: Telephone counseling presents its own set of challenges that should be investigated further to improve the quality of care and long-term patient outcomes.

Download Full-text